PharmaCyte Biotech’s $15 Million Follow-On Public Offering

Troutman Pepper Hamilton Sanders advised PharmaCyte Biotech, Inc. on the deal.PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now